{"id":27167,"date":"2021-05-26T15:26:27","date_gmt":"2021-05-26T13:26:27","guid":{"rendered":"https:\/\/www.satt.fr\/mablink-bioscience-lexpert-des-adc-nouvelle-generation-incubee-par-pulsalys-leve-4-millions-deuros\/"},"modified":"2021-05-26T15:26:27","modified_gmt":"2021-05-26T13:26:27","slug":"mablink-bioscience-lexpert-des-adc-nouvelle-generation-incubee-par-pulsalys-leve-4-millions-deuros","status":"publish","type":"post","link":"https:\/\/www.satt.fr\/en\/mablink-bioscience-lexpert-des-adc-nouvelle-generation-incubee-par-pulsalys-leve-4-millions-deuros\/","title":{"rendered":"Mablink Bioscience, l\u2019expert des ADC nouvelle g\u00e9n\u00e9ration incub\u00e9e par PULSALYS, l\u00e8ve 4 millions d\u2019euros"},"content":{"rendered":"<p><strong>Mablink Bioscience, une entreprise, incub\u00e9e par PULSALYS, d\u00e9veloppant la nouvelle g\u00e9n\u00e9ration d\u2019anticorps conjugu\u00e9s (\u201cantibody-drug conjugates\u201d (ADC)) bas\u00e9s sur sa plateforme propri\u00e9taire de drug-linker hydrophiles PSARlinkTM, a annonc\u00e9 avoir compl\u00e9t\u00e9 un tour d\u2019amor\u00e7age de 4M\u20ac aupr\u00e8s d\u2019un syndicat d\u2019investisseurs men\u00e9 par Elaia Partners et accompagn\u00e9 du fonds Pertinence Invest 2 (Sofimac Innovation, conseill\u00e9 par M\u00e9rieux Equity Partners), Sham Innovation Sant\u00e9 (conseill\u00e9 par Turennes Capital), la Fondation Fournier-Majoie, Simba Sant\u00e9 (Angelor) et Cr\u00e9dit Agricole Cr\u00e9ation.<\/strong><\/p>\n<p><strong><span style=\"color: #ff6600;\">Transformer le domaine des ADC pour traiter les cancers avec peu ou pas d\u2019options th\u00e9rapeutiques<\/span><\/strong><\/p>\n<p>Les ADC sont une nouvelle classe de m\u00e9dicaments qui fonctionnent sur le principe des missiles guid\u00e9s : un anticorps monoclonal est utilis\u00e9 pour transporter une mol\u00e9cule<br \/>cytotoxique extr\u00eamement puissante directement et sp\u00e9cifiquement \u00e0 l\u2019int\u00e9rieur des cellules canc\u00e9reuses pour les d\u00e9truire, tout en \u00e9pargnant les tissus sains.<\/p>\n<p>Gr\u00e2ce \u00e0 sa technologie propri\u00e9taire PSARlinkTM qui attache des mol\u00e9cules cytotoxiques aux anticorps, Mablink Bioscience vise \u00e0 transformer le domaine des ADC en d\u00e9multipliant leur index th\u00e9rapeutique et en \u00e9largissant le spectre des mol\u00e9cules actives utilisables, des cibles mol\u00e9culaires et des indications th\u00e9rapeutiques compatibles.<\/p>\n<p>Mablink Bioscience va utiliser les fonds apport\u00e9s pour construire un pipeline d\u2019ADC dirig\u00e9s contre plusieurs cancers pour lesquels il n\u2019y a, \u00e0 l\u2019heure actuelle, peu ou pas d\u2019options th\u00e9rapeutiques satisfaisantes.<\/p>\n<p><span style=\"color: #ff6600;\"><strong>Une plateforme brevet\u00e9e avec un potentiel r\u00e9volutionnaire pour les ADC<\/strong><\/span><\/p>\n<p>En seulement 2 ans, Mablink Bioscience a r\u00e9ussi \u00e0 compl\u00e9ter le d\u00e9veloppement technologique et la validation pr\u00e9clinique de PSARlinkTM, sa plateforme brevet\u00e9e d\u2019ADC, qui<br \/>permet la cr\u00e9ation d\u2019ADC de nouvelle g\u00e9n\u00e9ration. Ces ADC sont homog\u00e8nes, plus faciles \u00e0 produire mais surtout ils pr\u00e9sentent d\u2019excellentes propri\u00e9t\u00e9s pharmacologiques avec un potentiel de m\u00e9dicaments \u201cbest-in-class\u201d.\u00a0Ces validations ont \u00e9t\u00e9 rendues possible par le soutien de Bpifrance, PULSALYS (la SATT de Lyon et Saint Etienne), le CLARA (Canc\u00e9rop\u00f4le Lyon Auvergne Rh\u00f4ne-Alpes) et un investisseur priv\u00e9. Warren Viricel, CSO et co-fondateur de Mablink Bioscience a comment\u00e9 : <em>\u201cPSARlinkTM a le potentiel pour r\u00e9ellement changer la donne dans le traitement du cancer et cet investissement est la premi\u00e8re \u00e9tape pour nous permettre de rapidement amen\u00e9 nos ADC au stade du d\u00e9veloppement clinique.\u201d<\/em><\/p>\n<p>Jean-Guillaume Lafay, CEO et co-fondateur de Mablink Bioscience a ajout\u00e9 : <em>\u201cNous sommes impatients de renforcer et d\u2019acc\u00e9l\u00e9rer le d\u00e9veloppement de notre pipeline d\u2019ADC ainsi que de travailler avec nos investisseurs pour poursuivre le d\u00e9veloppement de Mablink Bioscience et emmener notre technologie th\u00e9rapeutique au stade clinique, pour qu\u2019elle puisse y changer la donne dans la mani\u00e8re d\u2019aider les patients atteints des cancers les plus difficiles \u00e0 traiter.&#8221;<\/em><\/p>\n<p>Florian Denis, Investment Director chez Elaia explique : <em>\u201cElaia est tr\u00e8s fier de mener ce tour de financement et d\u2019avoir rassembl\u00e9 cette syndication d\u2019investisseurs. La plateforme de Mablink Bioscience a une approche \u201cbest-in-class\u201d et a le potentiel pour \u00eatre \u00e0 l\u2019origine de la prochaine vague d\u2019innovation du secteur prometteur des anticorps conjugu\u00e9s. Jean-Guillaume Lafay et son \u00e9quipe ont produit des donn\u00e9es pr\u00e9cliniques encourageantes que nous sommes impatients d\u2019\u00e9tendre vers de nouveaux jalons cr\u00e9ateurs de valeur.\u201d<\/em><\/p>\n<p>J\u00e9r\u00e9mie Waicenberg, Senior Business Analyst chez M\u00e9rieux Equity Partners a comment\u00e9 : <em>\u201cNous sommes particuli\u00e8rement heureux de cet investissement de Pertinence Invest 2 dans la soci\u00e9t\u00e9 Mablink Bioscience qui va soutenir le d\u00e9veloppement d\u2019ADC de nouvelle g\u00e9n\u00e9ration issus de la plateforme de l\u2019entreprise et participer \u00e0 l\u2019effort pour des th\u00e9rapies anticanc\u00e9reuses plus efficaces\u201d<\/em><\/p>\n<p>Bervin Bouani, Investment Director chez Turenne Capital a d\u00e9clar\u00e9 : <em>\u201cNous sommes ravis et impatients de travailler au c\u00f4t\u00e9 du management de Mablink Bioscience et des autres investisseurs pour renforcer et \u00e9tendre les capacit\u00e9s et les actifs de l\u2019entreprise.\u201d<\/em><\/p>\n<p>J\u00e9r\u00f4me Majoie, CEO de la fondation belge Fondation Fournier-Majoie a indiqu\u00e9 qu\u2019il \u00e9tait <em>\u201cfier d\u2019apporter un soutien \u00e0 Mablink Bioscience qui a \u00e9t\u00e9 qualifi\u00e9 par son conseil scientifique comme l\u2019un des projets les plus prometteurs pour apporter aux patients des th\u00e9rapies anticanc\u00e9reuses am\u00e9lior\u00e9es\u201d.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Mablink Bioscience, l\u2019expert des ADC nouvelle g\u00e9n\u00e9ration incub\u00e9e par PULSALYS, a annonc\u00e9 avoir compl\u00e9t\u00e9 un tour d\u2019amor\u00e7age de 4M\u20ac aupr\u00e8s d\u2019un syndicat d\u2019investisseurs men\u00e9 par Elaia Partners et accompagn\u00e9 du fonds Pertinence Invest 2 (Sofimac Innovation, conseill\u00e9 par M\u00e9rieux Equity Partners), Sham Innovation Sant\u00e9 (conseill\u00e9 par Turennes Capital), la Fondation Fournier-Majoie, Simba Sant\u00e9 (Angelor) et Cr\u00e9dit Agricole Cr\u00e9ation.<\/p>\n","protected":false},"author":24,"featured_media":27169,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[567,568,604],"tags":[],"class_list":["post-27167","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-en","category-successstories-en","category-startup-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Mablink Bioscience, l\u2019expert des ADC nouvelle g\u00e9n\u00e9ration incub\u00e9e par PULSALYS, l\u00e8ve 4 millions d\u2019euros - R\u00e9seau SATT<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.satt.fr\/en\/mablink-bioscience-lexpert-des-adc-nouvelle-generation-incubee-par-pulsalys-leve-4-millions-deuros\/\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sylvain DUC\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.satt.fr\/en\/mablink-bioscience-lexpert-des-adc-nouvelle-generation-incubee-par-pulsalys-leve-4-millions-deuros\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.satt.fr\/en\/mablink-bioscience-lexpert-des-adc-nouvelle-generation-incubee-par-pulsalys-leve-4-millions-deuros\/\"},\"author\":{\"name\":\"Sylvain DUC\",\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/d6cfecbabebe684202068d45b736deca\"},\"headline\":\"Mablink Bioscience, l\u2019expert des ADC nouvelle g\u00e9n\u00e9ration incub\u00e9e par PULSALYS, l\u00e8ve 4 millions d\u2019euros\",\"datePublished\":\"2021-05-26T13:26:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.satt.fr\/en\/mablink-bioscience-lexpert-des-adc-nouvelle-generation-incubee-par-pulsalys-leve-4-millions-deuros\/\"},\"wordCount\":732,\"image\":{\"@id\":\"https:\/\/www.satt.fr\/en\/mablink-bioscience-lexpert-des-adc-nouvelle-generation-incubee-par-pulsalys-leve-4-millions-deuros\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2021\/05\/Levee-de-fonds-Mablink.jpg\",\"articleSection\":[\"News\",\"Success Stories\",\"Start-up\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.satt.fr\/en\/mablink-bioscience-lexpert-des-adc-nouvelle-generation-incubee-par-pulsalys-leve-4-millions-deuros\/\",\"url\":\"https:\/\/www.satt.fr\/en\/mablink-bioscience-lexpert-des-adc-nouvelle-generation-incubee-par-pulsalys-leve-4-millions-deuros\/\",\"name\":\"Mablink Bioscience, l\u2019expert des ADC nouvelle g\u00e9n\u00e9ration incub\u00e9e par PULSALYS, l\u00e8ve 4 millions d\u2019euros - R\u00e9seau SATT\",\"isPartOf\":{\"@id\":\"https:\/\/www.satt.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.satt.fr\/en\/mablink-bioscience-lexpert-des-adc-nouvelle-generation-incubee-par-pulsalys-leve-4-millions-deuros\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.satt.fr\/en\/mablink-bioscience-lexpert-des-adc-nouvelle-generation-incubee-par-pulsalys-leve-4-millions-deuros\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2021\/05\/Levee-de-fonds-Mablink.jpg\",\"datePublished\":\"2021-05-26T13:26:27+00:00\",\"author\":{\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/d6cfecbabebe684202068d45b736deca\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.satt.fr\/en\/mablink-bioscience-lexpert-des-adc-nouvelle-generation-incubee-par-pulsalys-leve-4-millions-deuros\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.satt.fr\/en\/mablink-bioscience-lexpert-des-adc-nouvelle-generation-incubee-par-pulsalys-leve-4-millions-deuros\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.satt.fr\/en\/mablink-bioscience-lexpert-des-adc-nouvelle-generation-incubee-par-pulsalys-leve-4-millions-deuros\/#primaryimage\",\"url\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2021\/05\/Levee-de-fonds-Mablink.jpg\",\"contentUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2021\/05\/Levee-de-fonds-Mablink.jpg\",\"width\":760,\"height\":520},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.satt.fr\/en\/mablink-bioscience-lexpert-des-adc-nouvelle-generation-incubee-par-pulsalys-leve-4-millions-deuros\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.satt.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mablink Bioscience, l\u2019expert des ADC nouvelle g\u00e9n\u00e9ration incub\u00e9e par PULSALYS, l\u00e8ve 4 millions d\u2019euros\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.satt.fr\/en\/#website\",\"url\":\"https:\/\/www.satt.fr\/en\/\",\"name\":\"R\u00e9seau SATT\",\"description\":\"Les Soci\u00e9t\u00e9s d&#039;Acc\u00e9l\u00e9ration du Transfert de Technologies\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.satt.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/d6cfecbabebe684202068d45b736deca\",\"name\":\"Sylvain DUC\",\"url\":\"https:\/\/www.satt.fr\/en\/author\/sylvain\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Mablink Bioscience, l\u2019expert des ADC nouvelle g\u00e9n\u00e9ration incub\u00e9e par PULSALYS, l\u00e8ve 4 millions d\u2019euros - R\u00e9seau SATT","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.satt.fr\/en\/mablink-bioscience-lexpert-des-adc-nouvelle-generation-incubee-par-pulsalys-leve-4-millions-deuros\/","twitter_misc":{"Written by":"Sylvain DUC","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.satt.fr\/en\/mablink-bioscience-lexpert-des-adc-nouvelle-generation-incubee-par-pulsalys-leve-4-millions-deuros\/#article","isPartOf":{"@id":"https:\/\/www.satt.fr\/en\/mablink-bioscience-lexpert-des-adc-nouvelle-generation-incubee-par-pulsalys-leve-4-millions-deuros\/"},"author":{"name":"Sylvain DUC","@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/d6cfecbabebe684202068d45b736deca"},"headline":"Mablink Bioscience, l\u2019expert des ADC nouvelle g\u00e9n\u00e9ration incub\u00e9e par PULSALYS, l\u00e8ve 4 millions d\u2019euros","datePublished":"2021-05-26T13:26:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.satt.fr\/en\/mablink-bioscience-lexpert-des-adc-nouvelle-generation-incubee-par-pulsalys-leve-4-millions-deuros\/"},"wordCount":732,"image":{"@id":"https:\/\/www.satt.fr\/en\/mablink-bioscience-lexpert-des-adc-nouvelle-generation-incubee-par-pulsalys-leve-4-millions-deuros\/#primaryimage"},"thumbnailUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2021\/05\/Levee-de-fonds-Mablink.jpg","articleSection":["News","Success Stories","Start-up"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.satt.fr\/en\/mablink-bioscience-lexpert-des-adc-nouvelle-generation-incubee-par-pulsalys-leve-4-millions-deuros\/","url":"https:\/\/www.satt.fr\/en\/mablink-bioscience-lexpert-des-adc-nouvelle-generation-incubee-par-pulsalys-leve-4-millions-deuros\/","name":"Mablink Bioscience, l\u2019expert des ADC nouvelle g\u00e9n\u00e9ration incub\u00e9e par PULSALYS, l\u00e8ve 4 millions d\u2019euros - R\u00e9seau SATT","isPartOf":{"@id":"https:\/\/www.satt.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.satt.fr\/en\/mablink-bioscience-lexpert-des-adc-nouvelle-generation-incubee-par-pulsalys-leve-4-millions-deuros\/#primaryimage"},"image":{"@id":"https:\/\/www.satt.fr\/en\/mablink-bioscience-lexpert-des-adc-nouvelle-generation-incubee-par-pulsalys-leve-4-millions-deuros\/#primaryimage"},"thumbnailUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2021\/05\/Levee-de-fonds-Mablink.jpg","datePublished":"2021-05-26T13:26:27+00:00","author":{"@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/d6cfecbabebe684202068d45b736deca"},"breadcrumb":{"@id":"https:\/\/www.satt.fr\/en\/mablink-bioscience-lexpert-des-adc-nouvelle-generation-incubee-par-pulsalys-leve-4-millions-deuros\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.satt.fr\/en\/mablink-bioscience-lexpert-des-adc-nouvelle-generation-incubee-par-pulsalys-leve-4-millions-deuros\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.satt.fr\/en\/mablink-bioscience-lexpert-des-adc-nouvelle-generation-incubee-par-pulsalys-leve-4-millions-deuros\/#primaryimage","url":"https:\/\/www.satt.fr\/wp-content\/uploads\/2021\/05\/Levee-de-fonds-Mablink.jpg","contentUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2021\/05\/Levee-de-fonds-Mablink.jpg","width":760,"height":520},{"@type":"BreadcrumbList","@id":"https:\/\/www.satt.fr\/en\/mablink-bioscience-lexpert-des-adc-nouvelle-generation-incubee-par-pulsalys-leve-4-millions-deuros\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.satt.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Mablink Bioscience, l\u2019expert des ADC nouvelle g\u00e9n\u00e9ration incub\u00e9e par PULSALYS, l\u00e8ve 4 millions d\u2019euros"}]},{"@type":"WebSite","@id":"https:\/\/www.satt.fr\/en\/#website","url":"https:\/\/www.satt.fr\/en\/","name":"R\u00e9seau SATT","description":"Les Soci\u00e9t\u00e9s d&#039;Acc\u00e9l\u00e9ration du Transfert de Technologies","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.satt.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/d6cfecbabebe684202068d45b736deca","name":"Sylvain DUC","url":"https:\/\/www.satt.fr\/en\/author\/sylvain\/"}]}},"_links":{"self":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/27167","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/users\/24"}],"replies":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/comments?post=27167"}],"version-history":[{"count":0,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/27167\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/media\/27169"}],"wp:attachment":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/media?parent=27167"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/categories?post=27167"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/tags?post=27167"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}